This newly formed department will establish a community of technology innovators at St. Jude, whose tools and techniques will accelerate scientific discovery and improve the understanding and diagnosis of catastrophic childhood diseases.   

Jilin University-A new study published in the Journal of Science Bulletin proposed an innovative conceptual mechanism known as the “orbital stabilisation effect” for the precise design of novel Sb-based single-atom catalysts (SACs) to achieve high activity and ultra-long durability in the oxygen reduction reaction (ORR).

In a paper published in National Science Review, a bottom-up isoprene emission inventory, including both biogenic and combustion sources, was developed and used to model the contributions of isoprene to secondary organic aerosol formation in China. The results show that emissions of isoprene from combustion sources contributed substantially to ambient secondary organic aerosol, particularly during winter.

Continuing in its mission to elucidate the role of metal nutrients in human biology, the Chang Lab also offers a possible treatment modality in which copper chelation shows promising results in certain lung cancers where cells have two related phenomena: a heightened transcription factor responding to oxidative stress and a diminished level of bioavailable copper. Copper imbalances have long been implicated in cancer cell growth and other disease states.

The analysis of over 6,400 research articles shows a significant rise in studies on hydrothermal pretreatment, with China leading the global research output. The findings underscore the potential of this green technology for converting lignocellulosic biomass into biofuels and bioproducts.

CAMBRIDGE, Mass., January 23 --- Insilico Medicine( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors. Currently, ISM6331 is the leading oncology program among Insilico's wholly owned AI-driven drug discovery pipelines, which was granted orphan drug designation (ODD) by the FDA for the treatment of mesothelioma.